Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Read more
NEWS & MEDIA
Read our recent announcements
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Press
October 26, 2026
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Read more
All
Press
Publications
Presentations
Press
September 3, 2025
Iambic to Present New Pre-Clinical NSCLC Data for IAM1363, a Selective Type II Inhibitor for HER2 Cancers, at the 2025 World Conference on Lung Cancer
Read more
Press
September 2, 2025
Iambic to Participate in September Investor Conferences
Read more
Presentation
August 18, 2025
Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25
Read more
Presentation
August 11, 2025
Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum
Read more
Presentation
August 6, 2025
Video: Iambic CEO Tom Miller Interview at the NASDAQ MarketSite
Read more
Press
August 5, 2025
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic’s Scientific Advisory Board
Read more
Presentation
August 1, 2025
Presentation and poster shared at the Gordon Research Conference: High Throughput Chemistry and Chemical Biology
Read more
Presentation
July 29, 2025
Video: Iambic Therapeutics CEO Tom Miller on NYSE Floor Talk
Read more
Presentation
July 22, 2025
Panel at the Decoding Bio AIxBio Summit at the NYSE
Read more
Press
Announcement
December 11, 2024
Iambic Therapeutics Announces Appointment of Peter Olson, Ph.D., as Chief Scientific Officer
Read more
Press
November 1, 2024
Previewing NeuralPLexer3: Towards fully AI-enabled Structure-Based Drug Discovery
Read more
Press
October 29, 2024
Nvidia-backed AI firm Iambic unveils drug discovery ‘breakthrough’
Read more
Press
October 29, 2024
Iambic Therapeutics Announces “Enchant,” an AI Platform that Predicts Clinical Outcomes from the Earliest Stages of Drug Discovery
Read more
Press
September 27, 2024
‍Iambic Therapeutics Named to the Endpoints 11 List of Biotech’s Most Promising Startups 
Read more
Press
September 26, 2024
Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery
Read more
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publication
Presentation
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Read more
Publication
December 7, 2025
Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery
Read more
Publication
December 3, 2025
San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models
Read more
Publication
October 19, 2025
A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations (ESMO 2025)
Read more
Publication
September 9, 2025
IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC
Read more
Publication
May 5, 2025
Enchant v2: Pushing the Boundaries of Predictive Drug Discovery
Read more
Publication
April 29, 2025
A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)
Read more
Publication
December 16, 2024
NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models
Read more
Publication
October 29, 2024
Enchant whitepaper: Breaking the data wall between lab and clinic
Read more
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publication
Presentation
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Read more
Presentation
January 13, 2026
JPM Healthcare Conference 2026 Company Presentation
Read more
Presentation
October 30, 2025
Promise & Reality: Decoding AI’s Impact On Drug Development
Read more
Presentation
October 28, 2025
From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery
Read more
Presentation
September 23, 2025
Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development
Read more
Presentation
September 22, 2025
Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance
Read more
Presentation
September 10, 2025
Predictive Drug Discovery with Enchant v2
Read more
Presentation
August 18, 2025
Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25
Read more
Presentation
August 11, 2025
Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum
Read more
For media requests
Contact our communications team at media@iambic.ai
Contact us
Better technology for better medicines
GET IN TOUCH
contact@iambic.ai
(619) 330-5499
COMPANY
AboutNews & MediaCareersContactInvestors
TECHNOLOGY
PlatformPipelinePartners
Privacy Policy
Terms of Use
Copyright © 2026 Iambic Therapeutics, Inc. All Rights Reserved.